.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Analyze global market entry opportunities
  • Identify first generic entrants

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Merck
Express Scripts
Accenture
Deloitte
QuintilesIMS
Farmers Insurance
Baxter
Fuji
Citi
Covington

Generated: June 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020925

« Back to Dashboard
NDA 020925 describes TAVIST-1, which is a drug marketed by Glaxosmithkline Cons and Novartis and is included in two NDAs. It is available from one supplier. Additional details are available on the TAVIST-1 profile page.

The generic ingredient in TAVIST-1 is clemastine fumarate. There are two drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the clemastine fumarate profile page.

Summary for NDA: 020925

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 020925

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
TAVIST-1
clemastine fumarate
TABLET;ORAL 020925 NDA Novartis Consumer Health, Inc. 0067-1190 0067-1190-08 1 BLISTER PACK in 1 CARTON (0067-1190-08) > 8 TABLET in 1 BLISTER PACK
TAVIST-1
clemastine fumarate
TABLET;ORAL 020925 NDA Novartis Consumer Health, Inc. 0067-1190 0067-1190-16 2 BLISTER PACK in 1 CARTON (0067-1190-16) > 16 TABLET in 1 BLISTER PACK

Summary for product number 001

Active Rx/OTC/Discontinued:OTCDosage:TABLET;ORALStrength1.34MG
Approval Date:Aug 21, 1992TE:RLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Moodys
Cipla
Covington
US Army
Harvard Business School
Julphar
US Department of Justice
Daiichi Sankyo
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot